Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT06026345
Recruiting Observational

Affera Global Registry

NCT06026345 · tracked via the Priya Life Science Spain tracker
Sponsor
Medtronic Cardiac Ablation Solutions
Phase
Observational
Started
2023-12-22
Last updated
2025-10-07

Condition(s) studied

Atrial Fibrillation

Investigational drug(s) / intervention(s)

Affera Platform

Affera Platform: A cardiac ablation will be performed using the Affera Platform

Study summary

The Affera Global Registry is a prospective, global, multi-center, observational post-market registry (PMR). The purpose of this study is to describe clinical performance and safety data in a broad patient population treated with the Affera Platform.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject is ≥ 18 years of age or minimum age as required by local regulations * Planned procedure using the commercially available Affera Platform * Willing and able to comply with study requirements and give IC (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements Exclusion Criteria: * Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager * Subject with exclusion criteria required by local law

Primary outcome measure(s)

  • Primary Objective #1 (Efficacy) — 12 Month Post Proceedure
    Estimate freedom from recurrence of the arrhythmia(s) treated at the study index ablation procedure using the Affera Platform.

Trial sites (12)

FacilityCityRegionStatus
Universitair Ziekenhuis Brussel Brussels Belgium Recruiting
IKEM - Institut Klinické a Experimentální Medicíny Prague Czechia Recruiting
Nemocnice Na Homolce Prague Czechia Recruiting
Hôpital Haut-Lévêque - CHU de Bordeaux Bordeaux France Recruiting
Clinique Pasteur Toulouse France Recruiting
Charité Universitätsmedizin Berlin, DHZC - Campus Charité Mitte Berlin Germany Recruiting
MVZ CCB Frankfurt und Main Taunus GbR Frankfurt Germany Recruiting
Universitäres Herzzentrum Hamburg Germany Recruiting
Beacon Hospital Dublin Ireland Recruiting
Inselspital - Universitätsspital Bern Bern Switzerland Recruiting
Royal Papworth Hospital NHS Foundation Trust Cambridge United Kingdom Recruiting
Imperial College Healthcare NHS Trust - Hammersmith Hospital London United Kingdom Recruiting

More Medtronic Cardiac Ablation Solutions trials in Spain

DiamondTemp Global Registry Active, not recruiting
PulseSelect™ PFA Global Registry Recruiting

Other trials for the same condition

A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation Active, not recruiting
STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Active, not recruiting
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF Recruiting
PulseSelect™ PFA Global Registry Recruiting
The Fourth Left Atrial Appendage Occlusion Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06026345 on ClinicalTrials.gov ↗ ← All trials in Spain